以再评价为契机的中药上市后系统研究  

Taking evaluation of post-marketing as point of cut-in to promote systematic research of traditional Chinese medicine

作　　者：王永炎[1] 王志飞[1] 谢雁鸣[1] 

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700

出　　处：《中国中药杂志》2014年第18期3421-3423,共3页China Journal of Chinese Materia Medica

基　　金：国家"重大新药创制"科技重大专项(2009ZX09502030)

摘　　要：中药上市后的研究是从应用到机制的系统研究,既要开展宏观的临床评价,又要以此为切入点开展微观的机制研究,而后再将机制研究的成果应用于临床,形成良性循环。这一系统的研究需跳出中医药学科的领域,以大科学的思维开展多学科合作来完成,应建立多学科的研究团队,切实发挥产学研联盟和多学科联合体的作用,寻求新型的举国体制,建立适宜的机制以保障其运行。Research on post-marketing Chinese medicine should he the systematic study from application to mechanism.Clinical evaluation is the basis of mechanism study,we can find the clue from clinical evaluation,then make a mechanism study to find the reason,then apply the results to clinic.So it is a virtuous circle.In order to achieve it,we cannot be limited to traditional Chinese medicine,we should form multi-disciplinary team under the direction of grand science thinking,try hard to put industry-university-research institute collaboration association to use,and if necessary,explore the new model of the whole nation system.An appropriate operation mechanism is very important.

关 键 词：中药上市后再评价 系统研究 机制研究 运行机制 

分 类 号：R288[医药卫生—中药学]